Executive Director of the Alliance for Natural Health, Robert Verkerk, stated: “Young girls in the UK—as well as their parents and guardians—deserve to have the full facts on the risks and benefits of this vaccine to help them make properly informed choices. The NHS position is that the vaccine is safe, but the facts would suggest otherwise. Presently, there are no adequate data available on the comparative risks of Cervarix and Gardasil. Neither is there adequate information on the factors which may predispose certain individuals to serious adverse reactions, nor about the duration and effectiveness of immunity following single and multiple vaccinations. It is in the public interest—and of utmost urgency—that these key questions are answered by an independent scientific review panel and are made public.”
GlaxoSmithKline’s cervical cancer vaccine Cervarix has won a green light from the World Health Organisation (WHO) for use in developing countries, although how the shot will be paid for has yet to be resolved. WHO “prequalification” is necessary for UN agencies and the non-profit GAVI Alliance to purchase the vaccine, and Glaxo said it hoped the move would help speed access to Cervarix globally.
Lancet Study Indicates Cervarix HPV Vaccine Effective Against The Five Most Common Cervical Cancer-Causing Viruses
A study, published in Tuesday’s issue of The Lancet, said that as well as protecting against the two most common virus types, the GlaxoSmithKline Plc’s Cervarix vaccine also provides protection against the next three most common cancer-causing virus types. GlaxoSmithKline Plc’s is Europe’s biggest drug company.
The Gardasil issues I researched were the relatively limited trial period, the sketchy trail data; the cost benefit of a drug that was design to prevent a cancer that has been declining in both incidence and mortality for over 40-years. Cervical cancer is easily detected by regular PAP screening and in the early stages, the most treatable cancer. The other aspect of Gardasil roll-up that didn’t pass the smell test was the Merck Marauder School of lobbying today for a more profitable tomorrow. Merck literally carpet-bombed the halls of power and influence with cash to get GARDASIL approved by the FDA (while holding up the Glaxo HPV-vaccine, Cervarix), they got Gardasil endorsed by the CDC and mandated in many states as yet another vaccine necessary to attend school, and managed to get state legislators to pass bills to force insurance companies to pay for the Gardasil shot. As I researched the payouts and pay offs of state, local and federal representatives, I asked when did safety go on sale? Then I found out about Merck paying doctors to go on the stump to endorse Gardasil. Some docs with great speaking skills picked up several hundred thousand dollars in a year. Then there was the scandal about “Medical Journal-Like’ publications written by ‘bought and paid for’ doctors who dutifully regurgitated the WORD according to Merck.
GlaxoSmithKline announced results of head-to-head trial data on its HPV vaccine. The company trumpeted the comparative study, saying that its Cervarix vaccine prompted a much stronger immune-system response than Merck’s Gardasil.
To date, GlaxoSmithKline’s HPV-vaccine, Cervarix has been approved in 95 countries around the world, including the 27 member states of the European Union (EU), Australia, Brazil, South Korea, Mexico and Taiwan. Licensing applications have been submitted in more than 20 additional countries including Japan and the United States. GSK also submitted the vaccine to the World Health Organization (WHO) for prequalification in September 2007.
GlaxoSmithKline has won another European contract for the cervical cancer vaccine Cervarix. The Dutch government selected Cervarix for a new program to vaccinate all girls aged 12 with a catch-up program for girls aged 13 to 16 in the second half of 2009. In the first year some 350,000 Dutch girls will get the jab.
It’s no mystery why Merck and Glaxo are jostling for ascendancy here. Estimates of the market for HPV- vaccines run to several billions, even if their use was restricted to prevention of cervical cancer. And anyone who doesn’t expect ‘HPV vaccine mission creep’ hasn’t noted Merck’s well documented market penetration Modus operandi.